drj logo

"*" indicates required fields

Name*
Address*
Address*
Password*
I agree to the Terms of Service and Privacy Policy*
Yes, of course I want to receive emails from DRJ!
This field is for validation purposes and should be left unchanged.

Already have an account? Log in

drj logo

Welcome to DRJ

Already registered user? Please login here

Login Form

Register
Forgot password? Click here to reset

Create new account
(it's completely free). Subscribe

x
Skip to content
Disaster Recovery Journal
  • EN ESPAÑOL
  • SIGN IN
  • SUBSCRIBE
  • THE JOURNAL
    • Why Subscribe to DRJ
    • Digital Edition
    • Article Submission
    • DRJ Annual Resource Directories
    • Article Archives
    • Career Spotlight
  • EVENTS
    • DRJ Spring 2023
    • DRJ Fall 2023
    • Other Industry Events
    • Schedule & Archive
  • WEBINARS
    • Upcoming Webinars
    • On Demand
  • MENTOR PROGRAM
  • DRJ ACADEMY
    • DRJ Academy
    • Beginner’s Guide to BC
  • RESOURCES
    • New to Business Continuity?
    • White Papers
    • DR Rules and Regs
    • Planning Groups
    • Business Directory
    • Business Resilience Decoded
    • DRJ Glossary of Business Continuity Terms
    • Careers
  • ABOUT
    • Advertise with DRJ
    • DE&I
    • Board and Committees
      • Executive Council Members
      • Editorial Advisory Board
      • Career Development Committee
      • Glossary Committee
      • Rules and Regulations Committee
  • Podcast

Siemens Healthineers Announces FDA Emergency Use Authorization For CLINITEST® Rapid COVID-19 Antigen Self-Test

by DRJ Editorial Team | December 29, 2021 | | 0 comments

  • The CLINITEST Rapid COVID-19 Antigen Self-Test has received FDA EUA for unsupervised self-testing for the SARS-CoV-2 virus by individuals age 14 and older (or adult-collected samples from individuals ages 2-13).
  • Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of COVID-19 exposure.
  • Through nationwide retail distribution, the new self-test will be made broadly available as COVID-19 testing needs continue to grow for individuals, families, and businesses.

TARRYTOWN, N.Y.–(BUSINESS WIRE)–Siemens Healthineers announces that the U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for the CLINITEST Rapid COVID-19 Antigen Self-Test,1, 2, 3 providing nationwide access to a new at-home or over-the-counter self-test as COVID-19 testing needs continue to grow for individuals, families, and businesses. The easy-to-use nasal swab test is intended to aid in the rapid detection of SARS-CoV-2 (the virus that causes COVID-19) and provides visually read test results in just 15 minutes. It is authorized for self-testing use by individuals age 14 and older or adult-collected samples from individuals ages 2 to 13 years. The test is expected to be available starting in January. Siemens Healthineers has secured dedicated production capacity for U.S. bound product in the tens of millions per month.


“Undetected COVID-19 exposure is a major driver of community spread. With the CLINITEST Rapid COVID-19 Antigen Self-Test, consumers will have access to a fast, reliable, and convenient test to provide additional safety,” said Christoph Pedain, PhD, Head of Point of Care Diagnostics, Siemens Healthineers. “Siemens Healthineers is proud to bring this high-quality test, already used and trusted by families, medical professionals, businesses and governments in many parts of the world, to the United States under FDA Emergency Use Authorization.”

The product comes in a specific configuration for the United States and has been evaluated in a study specifically designed for the U.S. market and fully conducted in the U.S. with laypersons, thereby covering currently circulating variants of SARS-CoV-2. Meeting the high threshold of the US FDA, the product is highly accurate, with sensitivity of 86.5% (95% CI: 79.6 to 91.3%) and a specificity of 99.3% (95% CI: 95.9 to 100.0%) compared to the nucleic acid (PCR) detection method. Sensitivity defines the test’s ability to produce a positive result in those infected with SARS-CoV-2 per the PCR reference method, and specificity defines the ability to produce a negative result in those not currently infected with SARS-CoV-2.

All clinical data has been established under Siemens Healthineers participation in the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics’ (RADx) Independent Test Assessment Program (ITAP).

“The CLINITEST Rapid COVID-19 Antigen Self-Test detects SARS-CoV-2 antigens in people who are actively infected with the virus, making important information more readily available,” added Dr. Pedain. “We’d like to thank the U.S. Government, specifically the National Institutes of Health Rapid Acceleration of Diagnostics’ Independent Test Assessment Program, for their partnership in bringing much needed tests to the American people. We know this is a critical time in this pandemic, and we will do our part in providing support.”

Reliable results can help consumers make confident, informed decisions about their daily lives, with the simplicity of a nasal swab test at home. Consumers who receive a positive test result should follow guidance from the Centers for Disease Control and Prevention (CDC) to isolate and take steps to mitigate the spread of COVID-19.

Siemens Healthineers response to the pandemic

Siemens Healthineers has distinguished itself as a provider of quality diagnostic assays to aid the fight against the COVID-19 pandemic. In addition to antibody, antigen, and molecular SARS-CoV-2 tests, Siemens Healthineers offers a broad diagnostics portfolio across point of care and laboratory applications to aid in the prognosis, treatment and follow-up of COVID-19 patients. The company’s broad and differentiated menu includes hematology, coagulation, cardiac, respiratory, inflammation and infectious disease panels. Blood gas testing and imaging solutions from Siemens Healthineers deliver actionable results that aid clinicians in caring for COVID-19 patients.

For further information on the CLINITEST Rapid COVID-19 Antigen Self-Test, please visit www.clinitest.siemens-healthineers.com/US.

1 Product availability varies by country. Distributed by Siemens Healthineers.

2 The FDA’s EUA decision is based on the company’s participation in the NIH Rapid Acceleration of Diagnostics’ (RADx) Independent Test Assessment Program (ITAP), which aims to accelerate the regulatory review and availability of high-quality, accurate and reliable OTC test to the American public.

3 In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an Emergency Use Authorization. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion. Further information is available at www.siemens-healthineers.com.

Contacts

For Journalists
Trade media:

Lance Longwell

Phone: +1 610-883-0788; Email: lance.longwell@siemens-healthineers.com

Business and financial media:

Ulrich Kuenzel

Phone: +49 162 2433492; Email: ulrich.kuenzel@siemens-healthineers.com

Related Content

  1. Disaster Recovery Journal
    The Difference a Hurricane Can Make: The Change of Louisiana’s Emergency Preparedness Effort
  2. Disaster Recovery Journal
    Public and Private Sector Relationships in Emergency Management
  3. Disaster Recovery Journal
    Safety Security and Loss Prevention During Hospitality Emergencies

Recent Posts

Keysight to Highlight Automotive Testing Innovations at ATE Europe 2023

June 5, 2023

Wipro Issues Public Announcement Regarding Buyback Offer

June 5, 2023

NCR to Participate in Upcoming Investor Conferences

June 5, 2023

J.P. Morgan Wealth Plan™ Recognized as Best Digital Initiative and Best Use of Technology

June 5, 2023

VBA Announces New Solution That Will Drastically Speed up Processing of Healthcare Claims

June 5, 2023

Annual G2 Survey: Despite Economic Headwinds, Businesses Are Increasing Software and Services Spend

June 5, 2023

Archives

  • June 2023 (147)
  • May 2023 (1206)
  • April 2023 (1145)
  • March 2023 (1336)
  • February 2023 (1154)
  • January 2023 (1391)
  • December 2022 (1144)
  • November 2022 (1595)
  • October 2022 (1574)
  • September 2022 (1571)
  • August 2022 (1581)
  • July 2022 (1365)
  • June 2022 (1711)
  • May 2022 (1651)
  • April 2022 (1618)
  • March 2022 (1924)
  • February 2022 (1549)
  • January 2022 (1472)
  • December 2021 (1446)
  • November 2021 (1835)
  • October 2021 (1777)
  • September 2021 (1697)
  • August 2021 (1661)
  • July 2021 (1566)
  • June 2021 (1768)
  • May 2021 (1666)
  • April 2021 (1798)
  • March 2021 (1907)
  • February 2021 (1038)
  • January 2021 (554)
  • December 2020 (30)
  • November 2020 (35)
  • October 2020 (48)
  • September 2020 (57)
  • August 2020 (52)
  • July 2020 (40)
  • June 2020 (72)
  • May 2020 (46)
  • April 2020 (59)
  • March 2020 (46)
  • February 2020 (28)
  • January 2020 (36)
  • December 2019 (22)
  • November 2019 (11)
  • October 2019 (36)
  • September 2019 (44)
  • August 2019 (77)
  • July 2019 (117)
  • June 2019 (106)
  • May 2019 (49)
  • April 2019 (47)
  • March 2019 (24)
  • February 2019 (37)
  • January 2019 (12)
  • ARTICLES & NEWS

    • Business Continuity
    • Disaster Recovery
    • Crisis Management & Communications
    • Risk Management
    • Article Archives
    • Industry News

    THE JOURNAL

    • Digital Edition
    • Advertising & Media Kit
    • Submit an Article
    • Career Spotlight

    RESOURCES

    • White Papers
    • Rules & Regulations
    • FAQs
    • Glossary of Terms
    • Industry Groups
    • Business & Resource Directory
    • Business Resilience Decoded
    • Careers

    EVENTS

    • Fall 2023

    WEBINARS

    • Watch Now
    • Upcoming

    CONTACT

    • Article Submission
    • Media Kit
    • Contact Us

    ABOUT DRJ

    Disaster Recovery Journal is the industry’s largest resource for business continuity, disaster recovery, crisis management, and risk management, reaching a global network of more than 138,000 professionals. Offering weekly webinars, the latest industry news, rules and regulations, podcasts, the industry’s only official mentoring program, a quarterly magazine, and two annual live conferences, DRJ is leading the way to keep professionals up-to-date and connected in an ever-changing world.

    LEARN MORE

    TWITTER

    Disaster Recovery Journal is the leading publication/event covering business continuity/disaster recovery.

    Follow us for daily updates @drjournal

    Newsletter

    The Journal, right in your inbox.

    Be informed and stay connected by getting the latest in news, events, webinars and whitepapers on Business Continuity and Disaster Recovery.

    Subscribe Now
    Copyright 2023 Disater Recovery Journal
    • Terms of Use
    • Privacy Policy